Free tool
FAERS Monitor: Kirsty
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761188 or its brand name (Kirsty, Insulin Aspart-Xjhz). Reports on generic versions are filed under their own applications.
Reports
660
Serious
447
68% of reports
Hospitalization
170
Death reported
56
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue42
- pain36
- dyspnoea33
- nausea33
- drug ineffective30
- off label use28
- vomiting28
- malaise27
- diarrhoea26
- headache26
- product dose omission issue26
- pyrexia26
- fall24
- death23
- weight decreased23
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 4 |
| 2008 | 5 |
| 2009 | 7 |
| 2010 | 11 |
| 2011 | 9 |
| 2012 | 15 |
| 2013 | 4 |
| 2014 | 32 |
| 2015 | 38 |
| 2016 | 21 |
| 2017 | 20 |
| 2018 | 25 |
| 2019 | 20 |
| 2020 | 16 |
| 2021 | 40 |
| 2022 | 80 |
| 2023 | 69 |
| 2024 | 51 |
| 2025 | 76 |
| 2026 | 107 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,499 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product dose omission issueSignal | 26 | 2.8 | 1.9 | 29 |
| weight decreasedSignal | 23 | 2.6 | 1.8 | 22 |
| pyrexiaSignal | 26 | 2.4 | 1.6 | 20 |
| fallSignal | 24 | 2.3 | 1.6 | 17 |
| malaise | 27 | 2.0 | 1.4 | 12 |
| vomiting | 28 | 1.9 | 1.3 | 11 |
| pain | 36 | 1.9 | 1.4 | 14 |
| dyspnoea | 33 | 1.9 | 1.3 | 13 |
| fatigue | 42 | 1.7 | 1.3 | 12 |
| nausea | 33 | 1.3 | 1.0 | 2 |
| headache | 26 | 1.3 | 0.9 | 2 |
| diarrhoea | 26 | 1.3 | 0.9 | 1 |
| off label use | 28 | 1.0 | 0.7 | 0 |
| death | 23 | 0.9 | 0.6 | 0 |
| drug ineffective | 30 | 0.7 | 0.5 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.